Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although it has long been appreciated that ovarian carcinoma subtypes (serous, clear cell, endometrioid, and mucinous) are associated with different natural histories, most ovarian carcinoma biomarker studies and current treatment protocols for women with this disease are not subtype specific. With the emergence of high-throughput molecular techniques, distinct pathogenetic pathways have been identified in these subtypes. We examined variation in biomarker expression rates between subtypes, and how this influences correlations between biomarker expression and stage at diagnosis or prognosis. METHODS AND FINDINGS: In this retrospective study we assessed the protein expression of 21 candidate tissue-based biomarkers (CA125, CRABP-II, EpCam, ER, F-Spondin, HE4, IGF2, K-Cadherin, Ki-67, KISS1, Matriptase, Mesothelin, MIF, MMP7, p21, p53, PAX8, PR, SLPI, TROP2, WT1) in a population-based cohort of 500 ovarian carcinomas that was collected over the period from 1984 to 2000. The expression of 20 of the 21 biomarkers differs significantly between subtypes, but does not vary across stage within each subtype. Survival analyses show that nine of the 21 biomarkers are prognostic indicators in the entire cohort but when analyzed by subtype only three remain prognostic indicators in the high-grade serous and none in the clear cell subtype. For example, tumor proliferation, as assessed by Ki-67 staining, varies markedly between different subtypes and is an unfavourable prognostic marker in the entire cohort (risk ratio [RR] 1.7, 95% confidence interval [CI] 1.2%-2.4%) but is not of prognostic significance within any subtype. Prognostic associations can even show an inverse correlation within the entire cohort, when compared to a specific subtype. For example, WT1 is more frequently expressed in high-grade serous carcinomas, an aggressive subtype, and is an unfavourable prognostic marker within the entire cohort of ovarian carcinomas (RR 1.7, 95% CI 1.2%-2.3%), but is a favourable prognostic marker within the high-grade serous subtype (RR 0.5, 95% CI 0.3%-0.8%). CONCLUSIONS: The association of biomarker expression with survival varies substantially between subtypes, and can easily be overlooked in whole cohort analyses. To avoid this effect, each subtype within a cohort should be analyzed discretely. Ovarian carcinoma subtypes are different diseases, and these differences should be reflected in clinical research study design and ultimately in the management of ovarian carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Shih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113 · cited 1×
“The dismal response rate of clear cell carcinomas (15%) contrasts sharply with that of high-grade serous (80%), resulting in a lower 5-y survival for clear cell compared with high-grade serous carcinoma in patients with advanced stage tumors (20% versus 30%) [7,8].”
BackgroundWright, G., Tan, B., Rosenwald, A., Hurt, E. H., Wiestner, A., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,040 · cited 1×
“, breast carcinoma and lymphoma [24,25]), and this subtype specific approach to treatment has implications for the design of clinical trials for women with ovarian carcinomas.”
BackgroundGrading Ovarian Serous Carcinoma Using a Two-Tier System
Malpica, A., Deavers, M. T., Lu, K., Bodurka, D. C., Atkinson, E. N., Gershenson, D. M., & Silva, E. G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200404000-00009 · Cited by 670 · cited 1×
“The serous subtype was further subdivided into low- and high-grade [11].”
BackgroundLu, K. H., Patterson, A. P., Wang, L., Marquez, R. T., Atkinson, E. N., Baggerly, K. A., Ramoth, L. R., Rosen, D. G., Liu, J., Hellstrom, I., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0409 · Cited by 440 · cited 1×
“For example, CA125 is expressed in most high-grade serous carcinoma, but only in 60% of mucinous and clear cell subtypes, a finding that is consistent with previous studies [26].”
ResultSchwartz, D. R., Kardia, S. L. R., Shedden, K., Kuick, R. D., Michailidis, G. C., Taylor, J. M. G., Misek, D. E., WU, R. T., Zhai, Y., Darrah, D. M., et al. (2002) · PubMed · Cited by 430
Singer, G., Stöhr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D.-F., Wang, T.-L., Kurman, R. J., & Shih, I.-M. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000146025.91953.8d · Cited by 408 · cited 1×
“The goal of our marker selection was to use proteins that are consistently expressed in ovarian carcinomas and have been reported as prognosticators (p53, p21, Ki-67, PR, WT1) [”
MethodZorn, K. K., Bonome, T., Gangi, L., Chandramouli, G. V. R., Awtrey, C. S., Gardner, G. J., Barrett, J. C., Boyd, J., & Birrer, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0508 · Cited by 376 · cited 1×
“Each of theses subtypes is associated with different genetic risk factors and molecular events during oncogenesis [1,2], and characterized by distinct mRNA expression profiles [3,4].”
Background
Research works printed but not linked: 2
- Swenerton KD 2008 Ovarian carcinoma treatment guidelines of the British Columbia Cancer Agency Available: http://www.bccancer.bc.ca/PPI/TypesofCancer/Ovary/default.htm. Accessed 1 April 2000
- Turbin DA Leung S 2008 GPEC plugin for Image J an image analyzing software Available: http://www.gpec.ubc.ca/index.php?content=software/imagej_plugin/index.php. Accessed 20 April 2008
Cited by
Items 601–700 of 895
Arora, N., Talhouk, A., McAlpine, J. N., Law, M. R., & Hanley, G. E. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2018-000040 · Cited by 8
Ahmad, B., Nawaz, S., Ali, S., Bashir, S., Mahmood, N., & Bushra, G. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.1.185 · Cited by 8
“Persistent abnormal level of CA-125 confirms > 95% certainty that the disease come back or is still present (Kobel et al., 2008).”
BackgroundDevelopment and application of antibody-drug conjugates in gynecological cancers
Zheng, R., Zhang, J., Zhou, J., Zhang, Z., Niu, M., Jing, F., Wu, K., Yi, M., & Li, T. (2025) · Science China Life Sciences · doi:10.1007/s11427-025-3016-4 · Cited by 7
“It is overexpressed in several cancer types, especially serous-type ovarian cancer, making it a promising target for ADCs (Köbel et al., 2008).”
In search of new prognostic molecular markers in ovarian cancer
Laatio, L. (2012) · Cited by 7
Jitmana, K., Griffiths, J. I., Fereday, S., DeFazio, A., Bowtell, D. D. L., Study, F. A. O. C., & Adler, F. R. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012073 · Cited by 7
“CA-125 levels differ across ovarian cancer subtypes, with HGSOC showing the highest average expression [16, 18].”
Ovaries, fallopian tubes and associated lesions
Manek, S., & Mahovlić, V. (2010) · Elsevier eBooks · doi:10.1016/b978-0-7020-3154-0.00027-2 · Cited by 7
Tissue Microarrays in Studying Gynecological Cancers
Page, C. L., Mes‐Masson, A., & Magliocco, A. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-396967-5.00005-0 · Cited by 7
Ünal, I., Khiavi, I. R., Kapaklı, G. E. T., Göksülük, D., Boyraz, G., Ozgul, N., Usubutün, A., Yürüker, S., & Zeybek, N. D. (2019) · Biotechnic & Histochemistry · doi:10.1080/10520295.2019.1627419 · Cited by 7
“High grade serous carcinomas are the most common epithelial ovarian cancers (Köbel et al. 2008).”
BackgroundHeublein, S., Anglesio, M. S., Marmé, F., & Kommoss, S. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02986-0 · Cited by 7
Ye, S., Zhou, S., Zhong, S., Shan, B., Jiang, W., Yang, W., Cai, X., & Yang, H. (2022) · BMC Cancer · doi:10.1186/s12885-022-09588-z · Cited by 7
“Background The histological subtypes of ovarian cancer are distinct diseases, each with different clinical and molecular characteristics [1].”
BackgroundCDH6 as a prognostic indicator and marker for chemotherapy in gliomas
Meng, M., Zhou, H., He, Y., Chen, L., Wang, W., Yang, L., Wang, Z., Zhang, L., & Wang, S. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.949552 · Cited by 7
“Studies have also found CDH6 expression in cases of ovarian carcinoma (Köbel et al., 2008) and thyroid cancers (Zhao et al.”
BackgroundHigh-Grade Serous Carcinoma Involving Fallopian Tube, Ovary and Peritoneum
Al‐Agha, O. M., & Gilks, C. B. (2011) · Surgical pathology clinics · doi:10.1016/j.path.2010.12.004 · Cited by 7
Self-citationLee, S. S., Park, J. S., Lee, K. B., Jeong, D. H., Byun, J. M., & Lee, S. M. (2021) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2021.22.4.1123 · Cited by 7
“Serum CA125 levels are high in serous carcinomas but low in mucinous and clear cell carcinomas (Lu et al., 2004; Kobel et al., 2008).”
BackgroundSTAMP alters the growth of transformed and ovarian cancer cells
He, Y., Blackford, J. A., Kohn, E. C., & Simons, S. S. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-128 · Cited by 7
“It has recently been suggested that ovarian cancer, like breast cancer, may be subdivided by differences in gene expression panels [24,25].”
Hocker, J. R. S., Bishop, E. A., Lightfoot, S. A., Lerner, M. R., Peyton, M. D., Brackett, D. J., Hanas, R. J., McMeekin, D. S., Walker, J. L., & Hanas, J. S. (2011) · Cancer Investigation · doi:10.3109/07357907.2011.636115 · Cited by 7
“tology cohort, but found no biomarkers in their group that distinguished early stage from late stage in the same histology sub-type (27).”
BackgroundGlaze, S., Nation, J. G., & Köbel, M. (2012) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)35322-1 · Cited by 7
Self-citationAli, E. T., Mohamed, N. S., Shafig, I. R., Muneer, M. S., Yosif, A. A., Hassan, L. A., Mohamed, A. M., Ahmed, A., & Siddig, E. E. (2020) · BMC Research Notes · doi:10.1186/s13104-020-05246-4 · Cited by 7
Peres, L. C., Bethea, T. N., Camacho, T. F., Bandera, E. V., Beeghly-Fadiel, A. C., Chyn, D., Harris, H. R., Joslin, C. E., Moorman, P. G., Myers, E. R., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa188 · Cited by 7
“Ovarian cancer is a heterogeneous disease composed of histotypes with unique pathologic, epidemiologic, molecular, and clinical features (2-5).”
BackgroundPAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis
Yun, B. S., Won, S., Kim, J.-H., Lee, N., Kim, M., Kim, M. K., Kim, M., Jung, Y. W., Kim, J. Y., Seong, S. J., et al. (2022) · Journal of Ovarian Research · doi:10.1186/s13048-022-00975-5 · Cited by 7
“In a recent study, hormone receptor expression, especially PR expression, is most common in endometrioid tumors but almost absent in clear call and mucinous carcinomas [22, 23].”
BackgroundRole of aberrant glycosylation in ovarian cancer dissemination
Sheta, R., & Bachvarov, D. R. (2014) · Biomedical Reviews · doi:10.14748/bmr.v25.1050 · Cited by 7
“indicate that EOC subtypes are different diseases and suggest that future biomarker identification and clinical research studies should investigate each EOC subtype separately (3).”
BackgroundMon, M. T., Yodkeeree, S., Punfa, W., Umsumarng, S., Lekwanavijit, S., Siriaunkgul, S., Suprasert, P., & Limtrakul, P. (2017) · PubMed Central · doi:10.22034/apjcp.2017.18.11.3063 · Cited by 7
“It has been proposed that the different subtypes may characterize different diseases (Soslow, 2008; Kobel et al., 2008).”
BackgroundNameki, R. A., Chang, H. S. Y., Yu, P. H., Abbasi, F., Lin, X., Reddy, J., Haro, M., Fonseca, M. A., Freedman, M. L., Drapkin, R., et al. (2023) · eLife · doi:10.7554/elife.86360.1 · Cited by 7
Multi-resolution Histopathology Patch Graphs for Ovarian Cancer Subtyping
Breen, J., Allen, K. E., Zucker, K., Orsi, N. M., & Ravikumar, N. (2025) · Lecture notes in computer science · doi:10.1007/978-3-031-83243-7_7 · Cited by 6
Cüylan, Z. F., Meydanlı, M. M., Sarı, M. E., Akbayır, Ö., Çelik, H., Dede, M., Şahin, H., Güngördük, K., Kuşçu, E., Özgül, N., et al. (2018) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13663 · Cited by 6
“Rather, EOCs are represented by a number of molecularly distinct diseases broadly defined by histotype with different routes of spread, patterns of relapse, response to chemotherapy and prognosis.(2)”
BackgroundRönnerman, E. W., Pettersson, D., Nemes, S., Dahm‐Kähler, P., Kovács, A., Karlsson, P., Parris, T. Z., & Helou, K. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1112152 · Cited by 6
“>10y 13 (26) 6 (35) 3 (27) 5 (29) 20 (45) 21 (72) 10 (56) 9 (45)”
InfluentialPGRMC1 and PAQR4 are promising molecular targets for a rare subtype of ovarian cancer
Kozłowska-Tomczyk, K., Borski, N., Głód, P., Gogola-Mruk, J., & Ptak, A. (2024) · Open Life Sciences · doi:10.1515/biol-2022-0982 · Cited by 6
Hanker, L., El‐Balat, A., Drosos, Z., Kommoss, S., Karn, T., Holtrich, U., Gitas, G., Graeser-Mayer, M. K., Anglesio, M. S., Huntsman, D. D., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03558-x · Cited by 6
Self-citationUpdate on ovarian cancer pathogenesis: history, controversies, emerging issues and future impact
Kalir, T., Firpo‐Betancourt, A., & Nezhat, F. R. (2013) · Expert Review of Obstetrics & Gynecology · doi:10.1586/17474108.2013.847638 · Cited by 6
Diebold, J. (2014) · Der Pathologe · doi:10.1007/s00292-014-1906-2 · Cited by 6
Post, M. D. (2011) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/j.ypat.2010.11.036 · Cited by 6
Karakaya, A. D., Durur-Subasi, İ., Karaman, A., Akçay, M. N., Palabıyık, Ş. S., Erdemci, B., Alper, F., & Acemoğlu, H. (2016) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000000390 · Cited by 6
Hassan, S. O. A., Nielsen, D. L., Tuxen, M. K., Petersen, P. H., & Sölétormos, G. (2017) · Future Science OA · doi:10.4155/fsoa-2017-0023 · Cited by 6
Matte, I., Bessette, P., & Piché, A. (2017) · InTech eBooks · doi:10.5772/intechopen.70993 · Cited by 6
“EOC encompasses ive histopathological subtypes with unique characteristics: high-grade serous carcinoma (HGSC), lowgrade serous carcinoma (LGSC), endometrioid carcinoma (EC), mucinous carcinoma (MC), and clear cell carcinoma [6, 7].”
BackgroundHada, T., Miyamoto, M., Ishibashi, H., Matsuura, H., Sakamoto, T., Kakimoto, S., Iwahashi, H., Suzuki, R., Tsuda, H., & Takano, M. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2237 · Cited by 6
Advances in sub-classification of ovarian carcinomas by cell type: an update
Seidman, J. D. (2014) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2014.07.005 · Cited by 6
Mondal, S. K., Basak, B., Bhattacharya, S., & Panda, U. K. (2021) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_311_19 · Cited by 6
Molecular Pathology of Ovarian Carcinomas
Köbel, M., & Huntsman, D. D. (2011) · Surgical pathology clinics · doi:10.1016/j.path.2010.12.009 · Cited by 6
Self-citationA Robust Deep Learning Framework for Ovarian Cancer Subtype Classification
Lv, S., & Zhang, G. (2024) · International Conference on Natural Computation, Fuzzy Systems and Knowledge Discovery (ICNC-FSKD) · doi:10.1109/icnc-fskd64080.2024.10702321 · Cited by 5
“Studies have also shown that the different subtypes are actually different diseases, so that specific treatment for the different subtypes is needed [3].”
BackgroundZwimpfer, T. A., Fereday, S., Pandey, A., Ariyaratne, D., Jayawardana, M., Twomey, L., Laumont, C. M., Kennedy, C. J., Bolithon, A., Meagher, N. S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71134-3 · Cited by 6
Self-citationMALDI-MSI and Ovarian Cancer Biomarkers
Longuespée, R., Boyon, C., Kerdraon, O., Vinatier, D., Fournier, I., Day, R. W., & Salzet, M. (2012) · InTech eBooks · doi:10.5772/24752 · Cited by 5
Chen, W., Lü, Y., Li, Q., Zhou, S., Hou, T., Yang, H., & Ye, S. (2025) · BMC Cancer · doi:10.1186/s12885-024-13389-x · Cited by 5
“It consists of different histologic subtypes, which are deemed to be distinct diseases with distinct clinical and molecular features [2, 3].”
Pedersen, S., Mohamed, A., Krzyslak, H., Al-Kaabi, L. S. S. A., AbuHaweeleh, M. N., Moustafa, A. A., Ghabreau, L., Vranić, S., & Honoré, B. (2025) · Współczesna Onkologia · doi:10.5114/wo.2025.149180 · Cited by 5
“Malignant ovarian tumors comprise three cell types: epithelial, stromal, and germ cells [6, 7].”
Rasool, I., Hussain, A. B., Assad, A., Masoodi, T., Bhat, M. R., & Macha, M. A. (2024) · International Journal of Systems Assurance Engineering and Management · doi:10.1007/s13198-024-02390-z · Cited by 5
Losi, L., Botticelli, L., Taccagni, G., Longinotti, E., Lancellotti, C., Scurani, L., & Zannoni, G. F. (2018) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2018.03.003 · Cited by 5
“Calretinin, CK5/6, D2-40 and WT1 are positive in more than 90% of mesotheliomas; however, they have also been shown to be expressed in approximately 10%, 25%, 65% and 90% of serous carcinomas, respectively (Kobel et al., 2008; Laury et al., 2010).”
Sheikh, U., Cohen, C., & Siddiqui, M. T. (2016) · Diagnostic Cytopathology · doi:10.1002/dc.23448 · Cited by 5
The Role of Steroid Receptors and HER2 in Ovarian Cancer
Barreta, M. C. D. A. (2014) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.1000158 · Cited by 5
“Although all this conflicting data is true to some extent it is important to emphasize that most ovarian cancer biomarker studies are not subtype specific and this can lead to misleading results [18].”
BackgroundQi, X., Zheng, X., Zong, B., Chen, Q.-Q., Zhang, F., Yang, X., Zhang, Y., Liu, J.-L., & Jiang, J. (2015) · PubMed · Cited by 5
Lopes‐Coelho, F., SILVA, F. A. B. N. D., Hipólito, A., Cardoso, B. A., & Serpa, J. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28209 · Cited by 5
“However, it is known that HNF1β is de novo expressed in clear cell carcinomas (CCC) and is classified as a CCC hallmark since > 90% of these cancer cells are HNF1β positive.(10,11) It is suggested that HNF1β plays an important role in the pathogenesis and behavior of CCC, acting on an oncogene‐like manner.”
BackgroundHistotype-specific analysis of acid ceramidase expression in ovarian cancer
El‐Balat, A., Karn, T., Holtrich, U., Becker, S., Kommoss, S., Győrffy, B., Anglesio, M. S., Huntsman, D. D., Drosos, Z., Rody, A., et al. (2020) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02728-0 · Cited by 5
Self-citationTessier‐Cloutier, B., Cochrane, D. R., Karnezis, A. N., Colborne, S., Magrill, J., Talhouk, A., Zhang, J., Leung, S. C. Y., Hughes, C. S., Piskorz, A., et al. (2020) · Human Pathology · doi:10.1016/j.humpath.2020.02.006 · Cited by 5
“6-mm cores from 237 cases of conventional HGSC was used [24].”
MethodSelf-citationOMICS for Tumor Biomarker Research
Moshkovskii, S. A., Pyatnitsky, M., Lokhov, P. G., & Baranova, A. V. (2015) · Biomarkers in disease · doi:10.1007/978-94-007-7681-4_14 · Cited by 5
The Disease Loophole: Index Terms and Their Role in Disease Misclassification
Roberts, A. N. (2024) · The Journal of Medicine and Philosophy A Forum for Bioethics and Philosophy of Medicine · doi:10.1093/jmp/jhae006 · Cited by 5
Schrader, K. A., Sharaf, R., Alanee, S. R., & Offit, K. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00012-6 · Cited by 5
Nameki, R. A., Chang, H. S. Y., Yu, P. H., Abbasi, F., Lin, X., Reddy, J., Haro, M., Fonseca, M. A., Freedman, M. L., Drapkin, R., et al. (2023) · eLife · doi:10.7554/elife.86360 · Cited by 5
Alexander, H. R., Jain, S., Gidwani, K., Ulfenborg, B., Ottander, U., Lundin, E., Hynninen, J., Ruma, S. A., Huhtinen, K., Sundfeldt, K., et al. (2025) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2025.114525 · Cited by 4
Tan, Q., Zhao, Y., Wu, Z., Kong, W., Xu, L., & Qu, F. (2025) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2025.118558 · Cited by 4
Lou, S. K., Hodgson, A., Nofech‐Mozes, S., Schwock, J., Olkhov‐Mitsel, E., Mirković, J., & Ghorab, Z. (2022) · Cancer Cytopathology · doi:10.1002/cncy.22642 · Cited by 4
“WT- 1 has been consistently reported to be positive in serous carcinoma at a range of 87% to 100%,(7,11,12) but only infrequently positive in other subtypes such as EAC and CCC (<10%).(13,14) Besides WT- 1 positivity, aberrant Figure 2.”
BackgroundPRIMER CONSENSO NACIONAL DE CÁNCER EPITELIAL DE OVARIO DIAGNÓSTICO Y TRATAMIENTO
Sánchez-Lander, J., Giampietro, L. D., Francisco Medina, E., Rodríguez, J. J., Rezic, M., Ledo, I. N. D., Calderaro, F. F., Negrín, L. C., Fernández, C., Cortiñas, P., et al. (2014) · Revista Venezolana de Oncología · Cited by 4
Jareid, M., Licaj, I., Olsen, K. S., Lund, E., & Bøvelstad, H. M. (2017) · International Journal of Cancer · doi:10.1002/ijc.30826 · Cited by 4
Qiu, C., Wang, Y., Wang, X., Zhang, Q., Li, Y., Xu, Y., Jin, C., Bu, H., Zheng, W., Yang, X., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4360 · Cited by 4
“These five subtypes are best considered to be distinct entities, of which serous type, accounting for 70% of EOC, is the most common (2,3).”
Vázquez, F. M., Basave, H. N. L., Herrera, M. D. C. M., & González, R. R. P. (2020) · American Journal of Case Reports · doi:10.12659/ajcr.925990 · Cited by 4
“8% of all cases, are a major risk factor in EOC [8].”
BackgroundFu, X., & Liu, Y. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-2609 · Cited by 4
“EOC is the most common histopathological type of ovarian cancer, accounting for about 80–90%, which is the highest among all gynecological malignancies (3).”
BackgroundRetractedNagarkar, R. V., Mamillapalli, G., Pal, S. K., Gupta, A., Saquib, N. M., Sagar, G., Rao, K. V. S., Siddiqui, Z., & Longkumer, I. (2024) · International Journal of Women s Health · doi:10.2147/ijwh.s444258 · Cited by 4
Skaggs, H. S., Saunders, B. A., Miller, R. W., Goodrich, S. T., King, M. S., Kimbler, K. D., Branscum, A. J., Fung, E. T., DePriest, P. D., van Nagell, J. R., et al. (2013) · Cancer Investigation · doi:10.3109/07357907.2013.802799 · Cited by 4
Unger, U., Denkert, C., Braicu, E. I., Sehouli, J., Dietel, M., Loibl, S., & Darb‐Esfahani, S. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-2050-6 · Cited by 4
“These studies were performed on mixed histological subtype cohorts and as these subtypes have distinct molecular and clinical characteristics as well as a presumed specific etiology, biomarkers can have rather varying clinical significance in each subtype [16].”
Gong, S., Chen, Y., Zhang, Y., Yao, W., Chen, L., Liu, S., & Wu, H. G. (2017) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1673-4254.2017.05.10 · Cited by 4
“[12]Koebel M, Kalloger SE, Boyd N, et al.”
BackgroundKaweesa, E. N., Bazioli, J. M., Pierre, H. C., Lantvit, D. D., Kulp, S. K., Hill, K. L., Phelps, M. A., Coss, C. C., Fuchs, J. R., Pearce, C. J., et al. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00069 · Cited by 4
Gilks, C. B. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9751-7_6 · Cited by 4
Self-citationWang, Y., Sun, H., Yu, A., Zhu, T., & Chen, X. (2019) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2019.09.004 · Cited by 4
Gavrielides, M. A., Ronnett, B. M., VANG, R. S., Sheikhzadeh, F., & Seidman, J. D. (2021) · Journal of Pathology Informatics · doi:10.4103/jpi.jpi_56_20 · Cited by 4
“Epithelial ovarian cancer is not one disease; it comprises at least five distinct histological subtypes,[26] namely high‐grade serous carcinoma (HGSC), low‐grade serous carcinoma (LGSC), clear cell carcinoma (CCC), endometrioid carcinoma (EC), and mucinous carcinoma (MUC), and a few less common variant subtypes.”
BackgroundHypoxia-induced Maspin Expression Affects the Prognosis of Ovarian Clear Cell Carcinoma
Lee, E. J., Park, S. J., Lee, C., Yim, G. W., Kim, J., & Kim, H. S. (2021) · In Vivo · doi:10.21873/invivo.12693 · Cited by 4
Molecular Profiling of Gynaecologic Malignancies: A Review
Shilpa, V. (2016) · Hereditary Genetics · doi:10.4172/2161-1041.1000158 · Cited by 4
“Mutations in KRAS, BRAF, PTEN, β-catenin (CTNNB1) and TGFBR2 genes have been reported in mucinous, endometrioid, and low-grade serous tumors and mutations in TP53, BRCA1, BRCA2, MLH1 and MSH2 genes have been reported in highgrade ovarian cancer subtypes [48].”
BackgroundOvarian cancer screening: UKCTOCS trial
Hoskins, P. J., & Gotlieb, W. H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30848-0 · Cited by 4
Evaluation of the role of autophagy in ovarian cancer chemoresistance
Quinn, J. E. (2020) · Cork Open Research Archive (University College Cork, Ireland) · Cited by 4
Prospective study of symptoms of ovarian cancer in postmenopausal women
Allen, P. (2010) · UCL Discovery (University College London) · Cited by 4
Zelisse, H. S., Asadi-Aghbolaghi, M., Farahani, H., Snijders, M. L. H., Hooijer, G. K. J., Mom, C. H., van Gent, M. D. J. M., Dijk, F., Horlings, H. M., van de Vijver, M. J., et al. (2025) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002481 · Cited by 3
Explainable Transfer Learning for Histopathological Image Classification of Ovarian Cancer
Rahman, M. M., Reem, S. Z., Rahaman, M. A., Bepery, C., Ashiqussalehin, M., & Hossain, M. J. (2025) · Journal of Computer Science and Technological Enquiry · doi:10.65496/jcste.2025.44 · Cited by 3
Zivic, K., Boljević, I., Nedeljković, M., Matović, M., Jankovic, R. N., & Tanić, M. (2026) · Cells · doi:10.3390/cells15030277 · Cited by 3
“Ovarian cancer is a heterogeneous disease with several histological subtypes that harbor different molecular characteristics [2].”
Clear cell borderline ovarian tumor: A retrospective study and literature review
Liu, Y., Wang, D., Jia, C., Su, N., Zhang, J., He, Y., Yang, J., & Xiang, Y. (2025) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2025.01.012 · Cited by 3
Wicaksono, A. W., Anggorowati, N., Kusumanto, A., Kurniadi, A., & Zucha, M. A. (2025) · Indian Journal of Gynecologic Oncology · doi:10.1007/s40944-025-00978-2 · Cited by 3
“[59].”
Gasimli, K., Wilke, A. M., Schmeil, I., Gasimli, B., Karn, T., Becker, S., Arsenić, R., & El‐Balat, A. (2025) · Gynecologic and Obstetric Investigation · doi:10.1159/000547773 · Cited by 3
“The heterogeneity of biomarker expression across histological subtypes may confound results if analyzed collectively [14].”
Ovarian Cancers: Their Varied Origins and Pathologically Implicated Microenvironment
Sun, Y., & Auersperg, N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813209-8.00032-7 · Cited by 3
Matsuura, T., Otsuka, I., O’uchi, T., O’uchi, E., Asano, R., & Miyasaka, N. (2021) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2021.01.009 · Cited by 3
Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics
Leung, F., Bernardini, M. Q., Liang, K., Batruch, I., Rouzbahman, M., Diamandis, E. P., & Kulasingam, V. (2018) · F1000Research · doi:10.12688/f1000research.13863.1 · Cited by 3
Lorenzini, J., deberti, M., Body, G., Carcopino, X., Touboul, C., Dabi, Y., Collinet, P., Coutant, C., Akladios, C. Y., Lavoué, V., et al. (2021) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2021.102242 · Cited by 3
EpCAM Expression in Epithelial Ovarian Cancer: Immunohistochemical and Histopathological Study
MOSTAFA, M. D. M. S. N. R. R., & SAMAR I. AMER, M. D. (2022) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2022.234835 · Cited by 3
OMICS for Tumor Biomarker Research
Moshkovskii, S. A., Pyatnitsky, M., Lokhov, P. G., & Baranova, A. V. (2014) · Springer eBooks · doi:10.1007/978-94-007-7744-6_14-1 · Cited by 3
Survivorship as an Element of Clinical Trials in Ovarian Cancer
McAlpine, J. N., & Wenzel, L. B. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31821bb717 · Cited by 3
Redjimi, N., Touboul, C., Émilie, D., Pallardy, M. J., Biola‐Vidamment, A., & Balabanian, K. (2012) · Cited by 3
Endometriosis-Associated Ovarian Cancer: The Role of Oxidative Stress
Yamashita, Y., & Toyokuni, S. (2012) · InTech eBooks · doi:10.5772/30541 · Cited by 3
Christophersen, M. K., Høgdall, C. K., & Høgdall, E. V. S. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4352 · Cited by 3
“The characteristics of particularly the four main EOc types differ markedly in origin tissue, gene and microRNA (miRNA) expression, and morphology, and there is emerging consensus that they should be recognised as four distinct diseases (6-8).”
BackgroundPrognostic biomarkers in ovarian carcinoma cyst fluid.
Kolwijck, E. (2010) · Radboud Repository (Radboud University) · Cited by 3
New Views of Ovarian Carcinoma Types: How Will This Change Practice?
Köbel, M., Kurman, R. J., & Seidman, J. D. (2013) · Springer eBooks · doi:10.1007/978-0-85729-910-9_3 · Cited by 2
Self-citationNew Progress of CA125 Surveillance in Diagnosis and Treatment of Ovarian Cancer
Du, K., & Tang, J. (2024) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2024.125004 · Cited by 2
Liquid biopsy in clinical practice: current evidence and future directions
Chenchula, S., Paraskar, G., Krishna, S., & Chavan, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27496-1.00010-5 · Cited by 2
Study of High Levels of Wilms’ Tumor 1 (WT1) Expression in Ovarian Cancers
Fatima, A., Pawar, S., Potpalle, D., Chandana, H., & Eshwar, M. D. (2026) · Cureus · doi:10.7759/cureus.104521 · Cited by 2
“In routine diagnostic pathology practice, immunohistochemistry serves as an essential adjunct to conventional histomorphological evaluation, particularly in cases with overlapping, ambiguous, or poorly differentiated microscopic features [7,8].”
Bahrami, F., McLeod, J., Pearce, C. L., Kushi, L. H., Garcia, C., Yong, P. J., Vera, M. A. D., McAlpine, J. N., Gamez, J. N. B., Tischer, K. M., et al. (2026) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djag251 · Cited by 2
Self-citationThe transcriptomic profile of ovarian cancer grading
Yao, C. Q., Nguyen, F., Haider, S. A., Starmans, M. H. W., Lambin, P., & Boutros, P. C. (2014) · Cancer Medicine · doi:10.1002/cam4.343 · Cited by 2
“Many subtypes of epithelial ovarian carcinoma exist including the serous, clear cell, endometrioid, and mucinous subtypes [2].”
BackgroundChen, L., Jin, C., Chen, B., Debora, A., Su, W., Zhou, Q., Zhou, S., Bian, J., Yang, Y., & Li, L. (2024) · British Journal of Radiology · doi:10.1093/bjr/tqae144 · Cited by 2
Tokalıoğlu, A. A., Özgün, Y. M., ÇELİK, F., Akdoğan, M., Bostancı, E. B., Turan, T., & Türkmen, O. (2022) · Transplantation Proceedings · doi:10.1016/j.transproceed.2021.12.004 · Cited by 2
Metadata
- Authors
- Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., Prentice, L. M., Miller, D., Santos, J., Swenerton, K., Gilks, C. B., & Huntsman, D.
- Affiliations
- BC Cancer Agency (CA)
- Canary Foundation (US)
- Georgia Institute of Technology (US)
- Corresponding author
- Huntsman, David
- ORCID
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 5
- Issue
- 12
- Pages
- e232
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC2592352
- OpenAlex
- W2129355295
- Cited by
- 814
- References
- 40
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 30 · 2023: 43 · 2022: 34 · 2021: 37 · 2020: 39 · 2019: 33 · 2018: 50 · 2017: 44 · 2016: 60 · 2015: 42 · 2014: 60 · 2013: 71 · 2012: 70
- FWCI
- 59.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Sanofi
- Canary Foundation
- Michael Smith Health Research BC
- Eli Lilly Canada
- Canadian Institutes of Health Research (017051)
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- ovarian carcinoma, histological subtypes, high-grade serous carcinoma, clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma, tumor markers, prognostic factors, Ki-67, WT1, CA125, HE4, stage at diagnosis, survival, molecular pathogenesis, tumor cell proliferation
- MeSH terms
- Carcinoma, Diagnosis, Differential, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Staging, Ovarian Diseases, Ovarian Neoplasms, Prognosis, Retrospective Studies, Biomarkers, Tumor, Cohort Studies, Confounding Factors, Epidemiologic, Survival Analysis, Tissue Array Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.